MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy

Cancer Research

Volumn 69, Issue 19, 2009, Pages 7803-7810

  Balakumaran, Bala S ^a   Porrello, Alessandro ^a   Hsu, David S ^a   Glover, Wayne ^a   Foye, Adam ^a   Leung, Janet Y ^a   Sullivan, Beth A ^a   Hahn, William C ^c,d   Loda, Massimo ^c   Febbo, Phillip G ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b DUKE CANCER INSTITUTE   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d BROAD INSTITUTE OF MIT AND HARVARD   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEZ 235; BINDING PROTEIN; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; MYC PROTEIN; RAPAMYCIN; UNCLASSIFIED DRUG;

ARTICLE; AUTOPHAGY; CONTROLLED STUDY; CYTOSTASIS; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN ANALYSIS; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; AUTOPHAGY; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E-BOX ELEMENTS; EUKARYOTIC INITIATION FACTOR-4E; GENES, MYC; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS C-MYC; SIROLIMUS; TOR SERINE-THREONINE KINASES; TUNICAMYCIN;

EID: 70350230219     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-0910     Document Type: Article

References (39)

1. Majumder PK, Febbo PG, Bikoff R, et al. mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways. Nat Med 2004;10:594-601. (Pubitemid 38796850)
2. +/- mice. Proc Natl Acad Sci U S A 2001; 98:10320-10325
3. Sarbassov dos D, Ali SM, Sabatini DM. Growing roles for the mTOR pathway. Curr Opin Cell Biol 2005; 17:596-603.
4. Hara K, Yonezawa K, Weng QP, Kozlowski MT, Belham C, Avruch J. Amino acid sufficiency and mTOR regulate p70 S6 kinase and eIF-4E BP1 through a common effector mechanism. J Biol Chem 1998;273:14484-14494 (Pubitemid 28319170)
5. Xu G, Kwon G, Cruz WS, Marshall CA, McDaniel ML. Metabolic regulation by leucine of translation initiation through the mTOR-signaling pathway by pancreatic β-cells. Diabetes 2001;50:353-360 (Pubitemid 32127292)
6. Dennis PB, Jaeschke A, Saitoh M, Fowler B, Kozma SC, Thomas G. Mammalian TOR: a homeostatic ATP sensor. Science 2001;294:1102-1105
7. Kim DH, Sarbassov DD, Ali SM, et al. mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 2002;110: 163-175
8. Hara K, Maruki Y, Long X, et al. Raptor, a binding partner of target of rapamycin (TOR), mediates TOR action. Cell 2002;110:177-189 (Pubitemid 34876546)
9. Kim DH, Sarbassov DD, Ali SM, et al. GβL, a positive regulator of the rapamycin-sensitive pathway required for the nutrient-sensitive interaction between raptor and mTOR. Mol Cell 2003;11:895-904.
10. Hashemolhosseini S, Nagamine Y, Morley SJ, Desrivieres S, Mercep L, Ferrari S. Rapamycin inhibition of the G1 to S transition is mediated by effects on cyclin D1 mRNA and protein stability. J Biol Chem 1998;273: 14424-14429 (Pubitemid 28319162)
11. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998;17: 769-780 (Pubitemid 28412498)
12. Jefferies HB, Reinhard C, Kozma SC, Thomas G. Rapamycin selectively represses translation of the "polypyrimidine tract" mRNA family. Proc Natl Acad Sci U S A 1994;91:4441-4445
13. Jefferies HB, Fumagalli S, Dennis PB, Reinhard C, Pearson RB, Thomas G. Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70S6K. EMBO J 1997;16:3693-3704 (Pubitemid 27250062)
14. Sarbassov DD, Ali SM, Kim DH, et al. Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol 2004;14:1296-1302
15. Jacinto E, Loewith R, Schmidt A, et al. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004;6:1122-1128 (Pubitemid 39468014)
16. Berger R, Febbo PG, Majumder PK, et al. Androgen-induced differentiation and tumorigenicity of human prostate epithelial cells. Cancer Res 2004;64:8867-8875 (Pubitemid 39665491)
17. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, Golub TR. Androgen mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 2005;173:1772-1777 (Pubitemid 40524830)
18. Boehm JS, Hession MT, Bulmer SE, Hahn WC. Transformation of human and murine fibroblasts without viral oncoproteins. Mol Cell Biol 2005;25: 6464-6474
19. Leung JY, Ehmann GL, Giangrande PH, Nevins JR. A role for Myc in facilitating transcription activation by E2F1. Oncogene 2008;27:4172-4179
20. Skehan P. Cytotoxicity and cell growth assays. In: Celis JE, editor. Cell biology: a laboratory handbook. 2nd ed. San Diego: Academic Press; 1998. p. 313-318
21. Singh D, Febbo PG, Ross K, et al. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002;1:203-209 (Pubitemid 41039166)
22. Bolstad BM, Irizarry RA, Astrand M, Speed TP. A comparison of normalization methods for high density oligonucleotide array data based on variance and bias. Bioinformatics 2003;19:185-193 (Pubitemid 36181903)
23. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 2003;31:e15.
24. Reiter RE, Sato I, Thomas G, et al. Coamplification of prostate stem cell antigen (PSCA) and MYC in locally advanced prostate cancer. Genes Chromosomes Cancer 2000;27:95-103.
25. Current protocols in molecular biology. John Wiley and sons; 2005. p. 21.3.1-33.
26. Neshat MS, Mellinghoff IK, Tran C, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 2001;98:10314-10319 (Pubitemid 32803017)
27. Stone K, Mickey D, Wunderli H, Mickey G, Paulson D. Isolation of a human prostate carcinoma cell line (DU 145). Int J Cancer 1978;21:274-281 (Pubitemid 8283045)
28. Kaighn M, Narayan K, Ohnuki Y, Lechner J, Jones L. Establishment and characterization of a human prostate carcinoma cell line (PC-3). Invest Urol 1979;17:16-23. (Pubitemid 9239413)
29. Horoszewicz JS, Leong SS, Kawinski E, et al. LNCaP model of human prostatic carcinoma. Cancer Res 1983; 43:1809-1818
30. Cao C, Subhawong T, Albert JM, et al. Inhibition of mammalian target of rapamycin or apoptotic pathway induces autophagy and radiosensitizes PTEN null prostate cancer cells. Cancer Res 2006;66:10040-10047 (Pubitemid 44672057)
31. Bello-Fernandez C, Packham G, Cleveland JL. The ornithine decarboxylase gene is a transcriptional target of c-Myc. Proc Natl Acad Sci U S A 1993;90:7804-7808 (Pubitemid 23250039)
32. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-274 (Pubitemid 44571966)
33. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-1806
34. McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008;455:1061-1068
35. Jenkins RB, Qian J, Lieber MM, Bostwick DG. Detection of c-myc oncogene amplification and chromosomal anomalies in metastatic prostatic carcinoma by fluorescence in situ hybridization. Cancer Res 1997;57:524-531 (Pubitemid 27081674)
36. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T. Genetic alterations in hormone-refractory recurrent prostate carcinomas. Am J Pathol 1998;153:141-148 (Pubitemid 28317516)
37. Mark HF, Samy M, Santoro K, Mark S, Feldman D. Fluorescent in situ hybridization study of c-myc oncogene copy number in prostate cancer. Exp Mol Pathol 2000;68:65-69 (Pubitemid 30082847)
38. Richter JD, Sonenberg N. Regulation of cap-dependent translation by eIF4E inhibitory proteins. Nature 2005;433:477-480 (Pubitemid 40204297)
39. Wang L, Rhodes CJ, Lawrence JC, Jr. Activation of mammalian target of rapamycin (mTOR) by insulin is associated with stimulation of 4EBP1 binding to dimeric mTOR complex 1. J Biol Chem 2006;281:24293-24303 (Pubitemid 44274202)